Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

viseslinger 68 posts  |  Last Activity: Aug 28, 2015 5:57 AM Member since: Oct 17, 2007
  • According to 3 Analysts, The short term target price has been estimated at $ 13.The target price could deviate by a maximum of $1.73 from the forecast price. In the near term, the target price could hit a high of $14 and a low of $ 11. 4 market experts have marked it as a strong buy. Oppenheimer initiates coverage on Agenus Inc. (NASDAQ:AGEN). In the latest research report, Oppenheimer announces the target price to $14 per share on the shares. According to the information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on June 10, 2015. Institutional Investors own 49.7% of Company shares. During last 3 month period, 63.35% of total institutional ownership has changed in the company shares.

    Sentiment: Strong Buy

  • Reply to

    Dec $130 puts

    by bonkenx Aug 27, 2015 6:47 PM
    viseslinger viseslinger Aug 27, 2015 10:59 PM Flag

    Your lost in space.

    Sentiment: Strong Sell

  • "Agenus Inc (NASDAQ:AGEN) advanced 1.22% to end last trading session at $6.65. The company, on July 24, 2015, declared that GlaxoSmithKline (GSK) received a positive opinion for its Malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The vaccine candidate, named Mosquirix™ (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision. Agenus’ adjuvant QS-21 is designed to increase immune response to antigens in vaccines. The positive opinion signals that Mosquirix meets the necessary quality, safety and efficacy requirements according to EU standards. Agenus is an immunology company involved in the discovery and development of novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases."

    Sentiment: Strong Buy

  • "Agenus Inc. (AGEN) finished above average on Tues with a 7-day performance of -10.62% closing at $6.65, up 1.22%. Wallstreet sold at a volume of 1,179,056 shares and relative volume of 0.74. Agenus Inc. (AGEN) holds a quarterly performance of -14.96% and is selling in the market off the company’s 52 week low by 159.77% and an overall debt to equity ratio of 0.13. Agenus Inc. (AGEN)’s performance per month comes in at -20.74%, overall insider transactions -16.45% and 84.3 million shares outstanding. Agenus Inc. (AGEN) is a buyer with an overall analyst rating of 1.7 and EPS growth this year of 36.60%"

    Sentiment: Strong Buy

  • Reply to

    Market musings.....

    by bmcgoo_03 Aug 22, 2015 12:03 PM
    viseslinger viseslinger Aug 27, 2015 6:45 AM Flag

    Most likely Melinda. She would then convince Warren.

    Sentiment: Strong Buy

  • "Agenus Inc. (AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, publicized that GlaxoSmithKline (GSK) received a positive opinion for its Malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The vaccine candidate, named Mosquirix™ (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision. Agenus’ adjuvant QS-21 is designed to increase immune response to antigens in vaccines. The positive opinion signals that Mosquirix meets the necessary quality, safety and efficacy requirements according to EU standards."

    Sentiment: Strong Buy

  • Reply to

    IBB up 3% this am

    by maddison3 Aug 26, 2015 7:55 AM
    viseslinger viseslinger Aug 26, 2015 9:51 PM Flag

    Maddi, only replying to your posts. Sad. Very Sad.

    Sentiment: Strong Sell

  • Reply to

    wonder why

    by maddison3 Aug 25, 2015 4:20 PM
    viseslinger viseslinger Aug 25, 2015 10:01 PM Flag

    Loser...

    Sentiment: Strong Sell

  • viseslinger viseslinger Aug 24, 2015 10:02 PM Flag

    no extra money for the mag. All spent on AGEN

    Sentiment: Strong Buy

  • Drugmakers are have seen big gains in the war on cancer by tapping the body's immune system, says this This week's cover story in Barron's. The promising new field of immuno-oncology is a potentially $30 billion market, and Barron's sees some likely winners -- yep you guessed it : AGEN

    Sentiment: Hold

  • viseslinger viseslinger Aug 24, 2015 8:13 PM Flag

    link please

    Sentiment: Buy

  • viseslinger viseslinger Aug 24, 2015 12:21 AM Flag

    Moreinfo, don't waste ur time with Sooz. She got her masters via online email service from China. Send $5 bucks and (2) box tops off cereal box and baboom your a masters econ & bus major.

    Sooz's probably still probably in middle school. Next Maddi will defend her, then Mr Turninu and then Mr know it all Jacosta. Remember super storm SANDY. THis is what is headed this way to big PHARMA. INCY better us their cash and buy back some stock or its sub 90 by Friday, eh Maddi?

    Sentiment: Hold

  • Reply to

    boy this all reminds of the crash of 1987

    by moreinfo424 Aug 20, 2015 11:12 PM
    viseslinger viseslinger Aug 23, 2015 10:07 PM Flag

    Maddi, VAZ says sell while you can. Credit crunch coming. Contango.

    Sentiment: Hold

  • Reply to

    boy this all reminds of the crash of 1987

    by moreinfo424 Aug 20, 2015 11:12 PM
    viseslinger viseslinger Aug 23, 2015 10:06 PM Flag

    Sooz will be buying at the open as INCY opens under a 100.... ECON 101. or did you clep out of that prereq.

    Sentiment: Hold

  • Reply to

    boy this all reminds of the crash of 1987

    by moreinfo424 Aug 20, 2015 11:12 PM
    viseslinger viseslinger Aug 23, 2015 7:50 AM Flag

    We agree on that. Had you gotten your phd (piled higher & deeper) you would know even less. Incy will experience contango and follow the trend of the oil patch. Soon the oil patch will turn to backwardation. INCY is longs ways from there. Maybe they didnt teach you this in supply & demand.

    Sentiment: Hold

  • Reply to

    Don't worry, be happy

    by jacosa Aug 21, 2015 2:29 PM
    viseslinger viseslinger Aug 21, 2015 5:28 PM Flag

    big pharma will put a hurt on Co(s) like incy. Interesting to hear spot oil prices in canada selling for $20 / brl and then they stock pile it in order to short WTI making it go contango. This to will soon happen to the pill pushers out there. Deflation is setting in. Hard to run a R&D co with deflation.

    Sentiment: Strong Sell

  • Reply to

    here comes 16500 just wait til monday

    by moreinfo424 Aug 21, 2015 2:58 PM
    viseslinger viseslinger Aug 21, 2015 5:24 PM Flag

    TJ, you were spot on, as it broke 16,500 by an additional 50 points. Sure wish Maddi could estimate as well as you. When will Maddi learn, up on Friday? Yea which Friday?

    Sentiment: Sell

  • Agenus could soon be the beneficiary of low-single-digit royalties tied to sales of two GlaxoSmithKline vaccines -- one for malaria and another for shingles -- that use Agenus' QS-21 Stimulon to improve their efficacy, but a bigger needle-moving opportunity may exist for Agenus in brain cancer.

    In phase 2 trials, Agenus Prophage vaccine delivered solid efficacy and safety results for use in patients with glioblastoma multiforme that include improved median progression-free survival and overall survival versus historical standard of care data.

    Progression-free survival in patients with low levels of PD-L1 expression was 27 months versus five to nine months and overall survival was 45 months versus 15 to 19 months. In patients with high PD-L1 expression, there was also a benefit, but it was less pronounced.

    As a result, Agenus is launching phase 3 trials of Prophage used alongside the current standard of care. If that approach succeeds, then Prophage could end up becoming part of a new go-to approach for treating the 27,000 Americans newly diagnosed with the disease every year and that could cause its shares to pop.

    Sentiment: Strong Buy

  • AZN and AGEN are paving the way for a new generation of breakthrough cancer drugs that boost the immune system's ability to detect and eradicate malignancies.
    Agenus' immuno-oncology platform has both an antibody discovery component and a compelling group of ready-made checkpoint modulator antibody candidates. As a result, pharmas like Incyte Corp. (NASDAQ:INCY) and Merck were quick to sign exploratory research deals with Agenus following its acquisition of 4-Antibody.

    Incyte is co-developing drug candidates for four checkpoint proteins (GITR, OX40, LAG-3, and TIM-3) with Agenus, paying the tiny biopharma $60 million total in a cash and stock deal. Merck, on the other hand, inked a deal worth up to $100 million in milestone payments, plus royalties, to develop drugs for two undisclosed therapeutic targets. Apparently this collaboration is going well, as Merck recently extended the discovery period to April 2016.

    Sentiment: Strong Buy

  • This collaboration with Agenus complements our active immuno-oncology discovery programs," Eric Rubin, M.D., vp, oncology clinical research with Merck Research Laboratories, said in a statement.

    Added Bob Stein, M.D., Ph.D., Agenus CSO: "We believe our Retrocyte Display technology has significant advantages for creation of high quality antibody development candidates. This collaboration broadens our efforts in immuno-oncology beyond our previously disclosed checkpoint programs with a world-class research and development partner."

    Agenus acquired the Retrocyte Display technology platform along with other assets of 4-Antibody when it bought the private European-based biopharmaceutical company in February. Retrocyte Display is designed to generate fully human therapeutic antibody drug candidates through its use of a high-throughput approach incorporating Immunoglobulin G (IgG) format human antibody libraries expressed in mammalian B-lineage cells.

    Agenus has multiple preclinical checkpoint modulator programs in development, some of which target checkpoint proteins GITR and OX40, as well as agonists and antagonists of TIM-3, LAG-3, PD-1 and CTLA-4. The latter two have shown promise in immuno-oncology clinical studies among checkpoint molecules that have bound with monoclonal antibodies designed to help immune cells overcome the checkpoint defenses of cancer cells. Through a collaboration with Ludwig Cancer Research, Agenus has programs to discover and develop fully human monoclonal antibodies that bind to key checkpoint proteins and activate or block their activities for use in cancer therapy.

    Sentiment: Strong Buy

INCY
119.93+6.08(+5.34%)Aug 28 4:00 PMEDT